Oruka Therapeutics (NASDAQ:ORKA) Shares Up 8.4% – Time to Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price was up 8.4% on Tuesday. The company traded as high as $112.16 and last traded at $113.3830. Approximately 1,215,407 shares changed hands during mid-day trading, an increase of 13% from the average daily volume of 1,077,189 shares. The stock had previously closed at $104.56.

Oruka Therapeutics News Summary

Investors following ORKA have been watching these news items:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a Buy rating, signaling continued analyst confidence. BTIG rating article UBS rating article
• Neutral Sentiment: Phase 2 psoriasis results are identified as a potential catalyst, but no new results were reported in the article; investors are still waiting for evidence of clinical progress. Phase 2 psoriasis article
• Negative Sentiment: HC Wainwright cut its EPS forecasts across Q4 2026, each quarter of 2027, and full-year 2026 and 2027, while keeping its Buy rating. Its FY2027 loss estimate widened to $3.22 per share from $2.82, pointing to a weaker near-term earnings outlook.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. BTIG Research restated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Mizuho set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Price Performance

The stock has a market capitalization of $7.14 billion, a P/E ratio of -49.89 and a beta of -0.34. The company has a fifty day moving average of $89.12 and a two-hundred day moving average of $71.65.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). As a group, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the transaction, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This trade represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at approximately $88,251,036.80. This represents a 2.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 169,950 shares of company stock valued at $15,426,080. Corporate insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ORKA. Nykredit A S bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $29,000. GAMMA Investing LLC grew its stake in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after buying an additional 250 shares during the last quarter. Orion Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $91,000. Sterling Capital Management LLC boosted its stake in Oruka Therapeutics by 839.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after purchasing an additional 1,485 shares during the period. Finally, Royal Bank of Canada grew its position in Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after purchasing an additional 2,033 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.